Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 63 of 102, showing 5 Applications out of 508 total, starting on record 311, ending on 315

# Protocol No Study Title Investigator(s) & Site(s)

311.

ECCT/21/05/06   VAC52150EBL2010 ;Phase 2
    An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen   
Principal Investigator(s)
1. Prof. Omu Anzala Omu Anzala
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

312.

ECCT/17/10/01   Neo-Fosfo
    Intravenous and Oral Fosfomycin in Hospitalised Neonates with Clinical Sepsis: an open-label safety and pharmacokinetics study   
Principal Investigator(s)
1. James A Berkley
Site(s) in Kenya
KEMRI-WTRP
 
View

313.

ECCT/13/03/02   An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples
    An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project   
Principal Investigator(s)
1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI
Site(s) in Kenya
1. THIKA (Nairobi City county)
 
View

314.

ECCT/13/04/03   HIV-Malaria Study_A5297
        An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of    Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 .   
Principal Investigator(s)
1. Josphat K. Kosgei
Site(s) in Kenya
1. Kemri Walter Reed Project-Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

315.

ECCT/20/10/04   yellow fever vaccine CVIA 079
    A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079.   
Principal Investigator(s)
1. Dr. Deborah Langat
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
View